Jonathan Edelman, senior vice president of CSL’s vaccines innovation unit, said the approval “marks a significant milestone” ...

FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes As a rapid-acting insulin, Merilo ...

BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive ...

Significant research news last week included a setback for Pliant Therapeutics, when it paused a Phase IIb trial of its bexotegrast in idiopathic pulmonary fibrosis (IPP). Also, US biotech AnaptysBio ...

Also in Europe, officials signed off on CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine, Kostaive, for use in individuals ages 18 and older. The approval is based on results ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive is the first in the new sa-mRNA class to be approved for marketing in the EU. The importance of biosimilars only continues to grow ...

KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA ...

Click here to see the full list of 230 stocks from our US High Growth Tech and AI Stocks screener. Let's uncover some gems from our specialized screener. Capricor Therapeutics Simply Wall St ...